Standard BioTools Inc. (LAB) Share buybacks
- Total buybacks · last 12 months (USD): Value $0.00; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2025-12-31..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2025-12-31..
Share buybacks
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $0.00 | Trailing-year cash paid for share repurchases. Period ending 2025-12-31. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 0.00 USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2025-12-31 | $0.00 | (m) | (m) |
| 2025-09-30 | $0.00 | (m) | (m) |
| 2025-06-30 | $0.00 | (m) | (m) |
| 2025-03-31 | $29.44M | (m) | (m) |
| 2024-12-31 | $40.49M | (m) | (m) |
| 2024-09-30 | $40.66M | (m) | (m) |
| 2024-06-30 | $41.06M | (m) | (m) |
| 2024-03-31 | $14.00M | (m) | (m) |
| 2023-12-31 | $5.41M | (m) | (m) |
| 2023-09-30 | $5.80M | (m) | (m) |
| 2023-06-30 | $5.40M | (m) | (m) |
| 2023-03-31 | $3.03M | (m) | (m) |
| 2022-12-31 | $563.00K | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |